COMPARISON
Degarelix vs Goserelin
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Degarelix is authorised or registered in 8 and Goserelin in 9 of the 10 registers read. Degarelix: highest phase Phase 3 (7 phase 3 trials, 0 with posted results). Goserelin: highest phase Phase 4 (after approval). 56 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Degarelix | Goserelin | |
|---|---|---|
| Registered trials differs | 187 clinicaltrials.gov · 2026-10-03 | 449 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: FIRMAGON openfda · 2026-10-03T17:23:44.062Z | FDA-approved: ZOLADEX openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2009-02-17 ema · 2026-10-03 | Not checked no record of "authorisedOn" for goserelin |
| ATC code differs | L02BX02 ema · 2026-10-03 | Not checked no record of "atcCode" for goserelin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Degarelix | placebo | Goserelin | placebo |
|---|---|---|---|---|
| Back pain | 4.9% | 9.2% | 22.7% | 21.4% |
| Hot flush | 4.3% | 0.8% | 35.2% | 34.7% |
| Injection site erythema | 14.1% | 0.0% | - | - |
| Injection site pain | 8.4% | 0.0% | - | - |
| Injection site induration | 7.8% | 0.0% | - | - |
| Hypertension | 6.2% | 7.1% | - | - |
| Prostatic specific antigen increased | 4.9% | 6.1% | - | - |
| Nasopharyngitis | 4.6% | 5.1% | - | - |
| Influenza | 4.2% | 5.1% | - | - |
| Headache | 2.9% | 5.1% | - | - |
| Neutropenia | - | - | 57.9% | 6.5% |
| Arthralgia | - | - | 38.8% | 36.2% |
| Neutrophil count decreased | - | - | 35.5% | 1.5% |
| Fatigue | - | - | 26.6% | 25.5% |
| Diarrhoea | - | - | 24.5% | 19.9% |
| Nausea | - | - | 23.1% | 19.1% |
| Anaemia | - | - | 21.8% | 11.0% |
| Leukopenia | - | - | 19.7% | 3.9% |
Trial register Degarelix: 2 placebo-controlled trials; Goserelin: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Degarelix side effects · Goserelin side effects
LEGAL STATUS
Approval in each country read
| Country | Degarelix | Goserelin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
56 registered trials include both
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING · updated 2026-09-14 |
|---|---|
| 2023-509494-23-00 | DARIUS : A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERM Not stated · updated 2026-09-07 |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging RECRUITING · updated 2026-08-19 |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatm ACTIVE_NOT_RECRUITING · updated 2026-08-17 |
| NCT05050084 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a ACTIVE_NOT_RECRUITING · updated 2026-08-17 |
| NCT04126070 | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors ACTIVE_NOT_RECRUITING · updated 2026-08-12 |
| NCT01786265 | Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer ACTIVE_NOT_RECRUITING · updated 2026-08-11 |
| NCT07751133 | Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer NOT_YET_RECRUITING · updated 2026-08-07 |
| NCT06378866 | Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy RECRUITING · updated 2026-07-20 |
| NCT02346253 | High-Dose Brachytherapy in Treating Patients With Prostate Cancer COMPLETED · updated 2026-07-02 |
| NCT05628363 | Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With Hig ACTIVE_NOT_RECRUITING · updated 2026-07-02 |
| NCT07313241 | Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER) RECRUITING · updated 2026-06-30 |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) RECRUITING · updated 2026-06-18 |
| NCT05617885 | Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer COMPLETED · updated 2026-06-16 |
| NCT07477626 | Radiotherapy After Prostatectomy for Node Positive Prostate Cancer RECRUITING · updated 2026-06-16 |
| 2023-506817-23-01 | EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) Not stated · updated 2026-06-08 |
| 2023-507482-26-00 | PEACE 8: Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer and oligometastases on functi Not stated · updated 2026-05-29 |
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer ACTIVE_NOT_RECRUITING · updated 2026-04-09 |
| NCT04787744 | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Can RECRUITING · updated 2026-04-08 |
| 2023-507970-42-00 | PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard Not stated · updated 2026-03-24 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.